A Study Evaluating TRIV-509 in Atopic Dermatitis (NCT07167758)
A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults With Moderate to Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.
Who can join: Review the eligibility criteria below.
Location: Triveni Bio Site #11 — Fountain Valley, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- Triveni Bio Site #11 — Fountain Valley, California
- Triveni Bio Site #4 — San Diego, California
- Triveni Bio Site #3 — Miami, Florida
- Triveni Bio Site #6 — Indianapolis, Indiana
- Triveni Bio Site #10 — South Bend, Indiana
- Triveni Bio Site #1 — Camp Hill, Pennsylvania
- Triveni Bio Site #16 — Bellaire, Texas
- Triveni Bio Site #5 — Dallas, Texas
- Triveni Bio Site #8 — Spokane, Washington
- Triveni Bio Site #38 — Pleven,
- Triveni Bio Site #39 — Sofia,
- Triveni Bio Site #13 — Ajax, Ontario
- Triveni Bio Site #17 — Newmarket, Ontario
- Triveni Bio Site #12 — Niagara Falls, Ontario
- Triveni Bio Site #15 — North York, Ontario
- Triveni Bio Site #22 — Ostrava,
- Triveni Bio Site #31 — Pardubice,
- Triveni Bio Site #21 — Prague,
- Triveni Bio Site #37 — Prague,
- Triveni Bio Site #23 — Prague,
- Triveni Bio Site #41 — Budapest,
- Triveni Bio Site #34 — Budapest,
- Triveni Bio Site #43 — Debrecen,
- Triveni Bio Site #33 — Wroclaw, Lower Silesian Voivodeship
- Triveni Bio Site #28 — Warsaw, Masovian Voivodeship
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.